RU2740849C2 - Способ, включающий фиксированное дробное дозирование цедираниба - Google Patents

Способ, включающий фиксированное дробное дозирование цедираниба Download PDF

Info

Publication number
RU2740849C2
RU2740849C2 RU2018131377A RU2018131377A RU2740849C2 RU 2740849 C2 RU2740849 C2 RU 2740849C2 RU 2018131377 A RU2018131377 A RU 2018131377A RU 2018131377 A RU2018131377 A RU 2018131377A RU 2740849 C2 RU2740849 C2 RU 2740849C2
Authority
RU
Russia
Prior art keywords
cediranib
days
composition
cancer
cancers
Prior art date
Application number
RU2018131377A
Other languages
English (en)
Russian (ru)
Other versions
RU2018131377A (ru
RU2018131377A3 (https=
Inventor
Саймон БАРРИ
Джейн КЕНДРЮ
Тони ХО
Стивен Роберт УЭДЖ
Сьюзан Перси АЙВИ
Элиз КОН
Джун-Мин ЛИ
Original Assignee
Астразенека Аб
ДЕ ЮНАЙТЕД СТЭЙТС ОФ АМЕРИКА, эз репрезентид бай ДЕ СЕКРЕТЭРИ, ДЕПАРТМЕНТ ОФ ХЕЛТ ЭНД ХЬЮМАН СЕРВИСЕЗ, Офис оф Текнолоджи Трансфер, Нейшнал Инститьютс оф Хелт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб, ДЕ ЮНАЙТЕД СТЭЙТС ОФ АМЕРИКА, эз репрезентид бай ДЕ СЕКРЕТЭРИ, ДЕПАРТМЕНТ ОФ ХЕЛТ ЭНД ХЬЮМАН СЕРВИСЕЗ, Офис оф Текнолоджи Трансфер, Нейшнал Инститьютс оф Хелт filed Critical Астразенека Аб
Publication of RU2018131377A publication Critical patent/RU2018131377A/ru
Publication of RU2018131377A3 publication Critical patent/RU2018131377A3/ru
Application granted granted Critical
Publication of RU2740849C2 publication Critical patent/RU2740849C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018131377A 2016-02-15 2017-02-14 Способ, включающий фиксированное дробное дозирование цедираниба RU2740849C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662295421P 2016-02-15 2016-02-15
US62/295,421 2016-02-15
PCT/US2017/017804 WO2017142871A1 (en) 2016-02-15 2017-02-14 Methods comprising fixed intermittent dosing of cediranib

Publications (3)

Publication Number Publication Date
RU2018131377A RU2018131377A (ru) 2020-03-17
RU2018131377A3 RU2018131377A3 (https=) 2020-06-02
RU2740849C2 true RU2740849C2 (ru) 2021-01-21

Family

ID=59625551

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018131377A RU2740849C2 (ru) 2016-02-15 2017-02-14 Способ, включающий фиксированное дробное дозирование цедираниба

Country Status (16)

Country Link
US (1) US20210322415A1 (https=)
EP (2) EP4071174A1 (https=)
JP (2) JP6865762B2 (https=)
KR (1) KR102830910B1 (https=)
CN (1) CN109073650A (https=)
AU (1) AU2017221268B2 (https=)
CA (1) CA3014674C (https=)
DK (1) DK3417294T3 (https=)
ES (1) ES2906813T3 (https=)
HU (1) HUE058114T2 (https=)
MA (1) MA44251A (https=)
MX (2) MX2018009867A (https=)
PL (1) PL3417294T3 (https=)
RU (1) RU2740849C2 (https=)
TW (1) TWI827530B (https=)
WO (1) WO2017142871A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2852460C2 (ru) * 2021-12-15 2025-12-08 Силладжен, Инк. Способы лечения неопластических заболеваний

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
EA202090655A1 (ru) * 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006035203A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Cancer combination therapy comprising azd2171 and imatinib

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
US20090035317A1 (en) * 2007-01-12 2009-02-05 Daugherty Patrick S Peptides binding to vascular endothelial growth factor
AU2009215375A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
CN102307475A (zh) * 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2013070976A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
JP6184423B2 (ja) * 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
CA2889182A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
KR20230076867A (ko) * 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
NO2714752T3 (https=) * 2014-05-08 2018-04-21
EP4245376A3 (en) * 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006035203A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Cancer combination therapy comprising azd2171 and imatinib

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KHARKOV E. I. et al., Cases of successful multiple cardioversion in recurrent ventricular fibrillation, Siberian Medical Review, 2012, T. 75, no. 3, pp. 82-85. *
KIERAN, M. W et al., A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Child's Nervous System, 2015, 31 (9), 1433-1445. doi: 10.1007 / s00381-015-2812-5. *
RYAN C. J et al., Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC), Invest New Drugs, 2007, 25:445-451.DOI 10.1007/s10637-007-9050-y. *
RYAN C. J et al., Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC), Invest New Drugs, 2007, 25:445-451.DOI 10.1007/s10637-007-9050-y. КIERAN, M. W et al., A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Child’s Nervous System, 2015, 31(9), 1433-1445. doi:10.1007/s00381-015-2812-5. ХАРЬКОВ Е. И. и др., Cлучаи успешной множественной кардиоверсии при рецидивирующей фибрилляции желудочков сердца, Сибирское медицинское обозрение, 2012, Т. 75, no. 3, С. 82-85. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2852460C2 (ru) * 2021-12-15 2025-12-08 Силладжен, Инк. Способы лечения неопластических заболеваний

Also Published As

Publication number Publication date
AU2017221268A1 (en) 2018-08-30
WO2017142871A8 (en) 2018-06-14
JP2021105039A (ja) 2021-07-26
CA3014674C (en) 2024-06-18
ES2906813T3 (es) 2022-04-20
HUE058114T2 (hu) 2022-07-28
KR102830910B1 (ko) 2025-07-04
CA3014674A1 (en) 2017-08-24
JP6865762B2 (ja) 2021-04-28
US20210322415A1 (en) 2021-10-21
MA44251A (fr) 2018-12-26
EP3417294B8 (en) 2022-05-04
AU2017221268B2 (en) 2024-02-15
CN109073650A (zh) 2018-12-21
EP3417294A1 (en) 2018-12-26
WO2017142871A1 (en) 2017-08-24
EP3417294B1 (en) 2021-12-01
RU2018131377A (ru) 2020-03-17
EP4071174A1 (en) 2022-10-12
KR20180125456A (ko) 2018-11-23
JP2019504860A (ja) 2019-02-21
TWI827530B (zh) 2024-01-01
MX2023007826A (es) 2023-07-07
DK3417294T3 (da) 2022-02-21
EP3417294A4 (en) 2019-08-14
PL3417294T3 (pl) 2022-05-09
JP7271594B2 (ja) 2023-05-11
TW201906610A (zh) 2019-02-16
MX2018009867A (es) 2019-05-27
RU2018131377A3 (https=) 2020-06-02

Similar Documents

Publication Publication Date Title
JP7271594B2 (ja) セジラニブの一定間欠投与を含む方法
JP2010503717A (ja) Ｅｇｆｒ変異を有する腫瘍を治療するための方法
WO2023196545A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
US20200086139A1 (en) Combination therapy for the treatment of glioblastoma
CN110730663B (zh) 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途
JP2019163288A (ja) 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤
EP3553083A1 (en) Combination therapy for the treatment of ovarian cancer
TW202128173A (zh) 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
US20200281923A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
TW202332431A (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
TW201906602A (zh) 癌症之治療方法
EP4159238A1 (en) Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody
TWI886356B (zh) 用於治療實性瘤之方法與包含ｋｒａｓｇ１２ｃ抑制劑及ｖｅｇｆ抑制劑之組成物
Sun et al. Systemic therapy for mutation-driven NSCLC
HK40000757B (en) Methods comprising fixed intermittent dosing of cediranib
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
JP2025159734A (ja) 抗線維化作用を有する低分子化合物と免疫チェックポイント制御剤との併用によるがん療法
UA128569C2 (uk) Дробне дозування модулятора глюкокортикоїдних рецепторів для лікування раку яєчника та інших видів раку
WO2025228596A1 (en) Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer
HK40105901A (zh) 糖皮质激素受体调节剂的间歇给予用於治疗卵巢癌和其他癌症
Xie The role of mesenchymal-epithelial transition factor (c-MET) in cancer development and treatments